NNovartis Read More Can Novartis’ Fabhalta Strengthen Its Nephrology Franchise?2026-07-17 Novartis NVS announced that the FDA has granted traditional approval to Fabhalta (iptacopan) for slowing kidney function decline…
NNovartis Read More FDA grants traditional approval to Novartis’ Fabhalta for IgAN2026-07-17 The US Food and Drug Administration (FDA) has issued traditional approval to Novartis for Fabhalta (iptacopan), to slow…
NNovartis Read More Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN2026-07-17 Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …
NNovartis Read More Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN2026-07-16 Novartis Pharma AG Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 …